A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2015-05-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 437
- Registration Number
- NCT00172042
- Locations
- 🇬🇧
Novartis Investigative Site, Sutton, United Kingdom
Renal Safety of Everolimus in Addition to Cyclosporine Microemulsion in Cardiac Transplant Recipients.
Phase 3
Completed
- Conditions
- Cardiac Transplantation
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT00170794
A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer
Phase 3
Completed
- Conditions
- Hormone Sensitive Resected Primary Breast Cancer in Postmenopausal Women
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 263
- Registration Number
- NCT00171704
- Locations
- 🇬🇧
Novartis Investigative Site, Sheffield, United Kingdom
Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 80
- Registration Number
- NCT00171899
- Locations
- 🇨🇦
Novartis Investigative Site, Toronto, Canada
An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT00171730
- Locations
- 🇺🇸
NYU / VA Medical Center, New York, New York, United States
🇨🇭Novartis Investigative Site, Lausanne, Switzerland
🇺🇸Cedars Sinai Medical Center Dept. of Pituitary Ctr., Los Angeles, California, United States
Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST)
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 64
- Registration Number
- NCT00171977
- Locations
- 🇯🇵
Novartis Investigative Site, Tokyo, Japan
A Study to Determine the Safety and Efficacy of Imatinib Mesylate in Patients With Idiopathic Hypereosinophilic Syndrome
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-05-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT00171860
- Locations
- 🇧🇪
Novartis Investigative Site, Leuven, Belgium
A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates
Phase 4
Completed
- Conditions
- Prostate Cancer With at Least One Bone Lesion in Patients Receiving Hormonal Therapy and Treatment With Bisphosphonates is Indicated
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-04-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 43
- Registration Number
- NCT00172016
The Effect of Tegaserod on Patterns of Flow in the Small Bowel of Patients With Irritable Bowel Syndrome (IBS)
Phase 3
Terminated
- Conditions
- Constipation PredominantIrritable Bowel Syndrome (IBS-C)
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-04-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT00171431
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-04-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1065
- Registration Number
- NCT00171340
- Locations
- 🇻🇪
Novartis Investigative Site, Caracas, Venezuela
🇹🇭Ratchathew, Khonkaen, Thailand
© Copyright 2025. All Rights Reserved by MedPath